Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company developing INTASYL® siRNA gene silencing technology for cancer treatment, has appointed David H. Deming to its Board of Directors effective February 19, 2025. Deming will serve on the Board's Nominating Committee, bringing the total board membership to 6 directors, with 5 being independent.
Deming brings over 30 years of experience in investment banking and asset management, including 27 years at JP Morgan where he led the Health Group in investment banking for 12 years. He later joined Integrated Finance , where he developed the SmartNest 401(k) asset allocation product, which was subsequently acquired by Dimensional Fund Advisors in 2010.
Phio Pharmaceuticals (NASDAQ: PHIO), una società biotecnologica in fase clinica che sviluppa la tecnologia di silenziamento genico INTASYL® siRNA per il trattamento del cancro, ha nominato David H. Deming nel suo Consiglio di Amministrazione con effetto dal 19 febbraio 2025. Deming farà parte del Comitato per le Nomine del Consiglio, portando il totale dei membri del consiglio a 6 direttori, di cui 5 indipendenti.
Deming porta con sé oltre 30 anni di esperienza nel settore della banca d'investimento e della gestione patrimoniale, tra cui 27 anni trascorsi presso JP Morgan, dove ha guidato il Gruppo Salute nella banca d'investimento per 12 anni. Successivamente è entrato a far parte di Integrated Finance, dove ha sviluppato il prodotto di allocazione degli asset SmartNest 401(k), che è stato successivamente acquisito da Dimensional Fund Advisors nel 2010.
Phio Pharmaceuticals (NASDAQ: PHIO), una empresa de biotecnología en etapa clínica que desarrolla la tecnología de silenciamiento génico INTASYL® siRNA para el tratamiento del cáncer, ha nombrado a David H. Deming en su Junta Directiva con efecto a partir del 19 de febrero de 2025. Deming formará parte del Comité de Nominaciones de la Junta, aumentando el total de miembros de la junta a 6 directores, de los cuales 5 son independientes.
Deming aporta más de 30 años de experiencia en banca de inversión y gestión de activos, incluyendo 27 años en JP Morgan, donde lideró el Grupo de Salud en banca de inversión durante 12 años. Luego se unió a Integrated Finance, donde desarrolló el producto de asignación de activos SmartNest 401(k), que fue adquirido posteriormente por Dimensional Fund Advisors en 2010.
Phio Pharmaceuticals (NASDAQ: PHIO)는 암 치료를 위한 INTASYL® siRNA 유전자 침묵 기술을 개발하는 임상 단계의 생명공학 회사로, David H. Deming을 2025년 2월 19일부터 이사회에 임명했습니다. Deming은 이사회의 추천 위원회에서 활동하게 되며, 이사회 총원은 6명의 이사로 증가하고 그 중 5명은 독립 이사입니다.
Deming은 투자은행 및 자산 관리 분야에서 30년 이상의 경험을 가지고 있으며, 그 중 27년은 JP Morgan에서 보냈고, 그곳에서 12년 동안 건강 그룹을 이끌었습니다. 이후 Integrated Finance에 합류하여 SmartNest 401(k) 자산 할당 제품을 개발하였고, 이 제품은 2010년에 Dimensional Fund Advisors에 의해 인수되었습니다.
Phio Pharmaceuticals (NASDAQ: PHIO), une entreprise de biotechnologie en phase clinique développant la technologie de silençage génique INTASYL® siRNA pour le traitement du cancer, a nommé David H. Deming à son Conseil d'Administration, avec effet au 19 février 2025. Deming siégera au Comité des Nominations du Conseil, portant le nombre total de membres du conseil à 6 administrateurs, dont 5 indépendants.
Deming apporte plus de 30 ans d'expérience dans la banque d'investissement et la gestion d'actifs, dont 27 ans chez JP Morgan, où il a dirigé le groupe santé dans la banque d'investissement pendant 12 ans. Il a ensuite rejoint Integrated Finance, où il a développé le produit d'allocation d'actifs SmartNest 401(k), qui a été acquis par Dimensional Fund Advisors en 2010.
Phio Pharmaceuticals (NASDAQ: PHIO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das die INTASYL® siRNA-Gentechnologie zur Krebsbehandlung entwickelt, hat David H. Deming mit Wirkung zum 19. Februar 2025 in seinen Vorstand berufen. Deming wird im Nominierungsausschuss des Vorstands tätig sein, wodurch die Gesamtzahl der Vorstandsmitglieder auf 6 Direktoren erhöht wird, von denen 5 unabhängig sind.
Deming bringt über 30 Jahre Erfahrung in der Investmentbanking- und Vermögensverwaltungsbranche mit, darunter 27 Jahre bei JP Morgan, wo er 12 Jahre lang die Gesundheitsgruppe im Investmentbanking leitete. Später trat er Integrated Finance bei, wo er das Produkt zur Vermögensallokation SmartNest 401(k) entwickelte, das 2010 von Dimensional Fund Advisors übernommen wurde.
- Addition of director with extensive healthcare investment banking experience
- Maintains strong board independence with 5 out of 6 directors being independent
- None.
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent.
"Mr. Deming's extensive experience in in the biopharma sector, both through his investment banking career and service on a number of corporate boards provides a valuable resource to Phio as we pursue our mission to advance our gene silencing technology for a cancer free future." said Robert Bitterman, CEO and Chairman of the Board.
David Deming has over 30 years of experience in investment banking and asset management. He was with JP Morgan for over 27 years in both M&A and leading the Health Group in investment banking for his last 12 years there. After leaving JP Morgan, he joined Integrated Finance Limited where he developed the SmartNest 401(k) asset allocation product which was sold to Dimensional Fund Advisors in 2010. David graduated from Hobart College with a Bachelor of Arts degree in Economics. He served on the Hobart and William Smith Colleges Board of Trustees for 15 years, serving 9 years as Chairman.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL has also demonstrated enhancement adoptive cell therapy. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target.
Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma in second quarter of 2023.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241363
FAQ
When did David Deming join Phio Pharmaceuticals (PHIO) Board of Directors?
What is David Deming's background before joining PHIO's board?
How many independent directors does PHIO have after Deming's appointment?
What committee will David Deming serve on PHIO's board?
